REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
04/08/2025
Voltar para busca
Dado oficial do USPTO
M
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: MistaEscritório: Estados Unidos
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
64
Atualização mais recente
05/08/2025
Tipo de marca
Mista
Classes Nice
5, 40, 42
Data de depósito
19/02/2016
Data de registro
04/08/2020
Data de expiração
-
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
04/08/2020
Última transação
05/08/2025
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Fundamento do pedido
Intent to use, Foreign priority
Código do desenho
5
Tipo de titular
03
Localização do titular
Quebec (Quebec), CA
Examinador
SHINER,MARK W
Unidade examinadora
L50
Localização atual
PUBLICATION AND ISSUE SECTION
Descrição da marca
The mark consists of the letter "M" in stylized font.
Titulares e representantes
Titulares
MEDICAGO INC.
Representantes
Michelle P. Ciotola CANTOR COLBURN LLP
Classificação técnica
Classes Nice
Classe 5Classe 40Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceutical and medicinal preparations and substanceshuman vaccinestherapeutic proteins and antibodies for treatment of infectious diseaseschronic diseases and cancer
Classe 40
Manufacture of pharmaceuticalspharmaceutical ingredientsvaccines and antibodies for others
Classe 42
Research and development in the field of vaccinesrecombinant proteins and antibodies for therapeutic and prophylactic use; high throughput vaccine engineering services; medical and scientific research services of proprietary recombinant protein platform technologies designed to lead to new human vaccinestherapeutic proteins and antibodies; product research and development and scientific research in the field of protein production using recombinant technologies through transient expression in plants; medical and scientific research services relating to infectious diseases; medical and scientific research regarding clinical trial studies on new vaccine candidates; development of pharmaceuticalspharmaceutical ingredientsvaccinesantibodies
Publicações
Histórico de despachos e eventos da marca no USPTO.
64 publicações encontradas
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
11/08/2023
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
11/08/2023
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
11/08/2023
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
04/05/2023
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
04/05/2023
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
04/05/2023
EWAF
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
04/05/2023
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
04/05/2023
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
04/05/2023
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
04/05/2023
R.PR
REGISTERED-PRINCIPAL REGISTER
04/08/2020
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
19/05/2020
PUBO
PUBLISHED FOR OPPOSITION
19/05/2020
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
29/04/2020
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
13/04/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
27/03/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
27/03/2020
ERSI
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
25/03/2020
GNS2
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
01/10/2019
GNSI
INQUIRY TO SUSPENSION E-MAILED
01/10/2019
CNSI
SUSPENSION INQUIRY WRITTEN
01/10/2019
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
18/03/2019
GNSL
LETTER OF SUSPENSION E-MAILED
18/03/2019
CNSL
SUSPENSION LETTER WRITTEN
18/03/2019
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
18/03/2019
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
18/03/2019
ERSI
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
15/03/2019
GNS2
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
21/09/2018
GNSI
INQUIRY TO SUSPENSION E-MAILED
21/09/2018
CNSI
SUSPENSION INQUIRY WRITTEN
21/09/2018
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
21/03/2018
GNSL
LETTER OF SUSPENSION E-MAILED
21/03/2018
CNSL
SUSPENSION LETTER WRITTEN
21/03/2018
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
21/03/2018
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
21/03/2018
ERSI
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
20/03/2018
GNS2
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
26/10/2017
GNSI
INQUIRY TO SUSPENSION E-MAILED
26/10/2017
CNSI
SUSPENSION INQUIRY WRITTEN
26/10/2017
RCCK
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
24/10/2017
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
24/04/2017
GNSL
LETTER OF SUSPENSION E-MAILED
24/04/2017
CNSL
SUSPENSION LETTER WRITTEN
24/04/2017
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
12/04/2017
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
12/04/2017
ERSI
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
05/04/2017
GNS2
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
11/11/2016
GNSI
INQUIRY TO SUSPENSION E-MAILED
11/11/2016
CNSI
SUSPENSION INQUIRY WRITTEN
11/11/2016
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
11/05/2016
GNSL
LETTER OF SUSPENSION E-MAILED
11/05/2016
CNSL
SUSPENSION LETTER WRITTEN
11/05/2016
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
11/05/2016
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
11/05/2016
ALIE
ASSIGNED TO LIE
06/05/2016
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
22/04/2016
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
04/03/2016
GNRT
NON-FINAL ACTION E-MAILED
04/03/2016
CNRT
NON-FINAL ACTION WRITTEN
04/03/2016
DOCK
ASSIGNED TO EXAMINER
02/03/2016
MPMK
NOTICE OF PSEUDO MARK E-MAILED
26/02/2016
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
25/02/2016
NWAP
NEW APPLICATION ENTERED
23/02/2016
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace M ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.